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Summary We describe melphalan pharmacokinetics in 26 patients treated by isolated limb perfusion (ILP).
Group A (n = 11) were treated with a bolus of melphalan (1.5 mg kg-'), and in a phase I study the dose was
increased to 1.75 mg kg-'. The higher dose was given as a bolus to Group B (n = 9), and by divided dose to
Group C (n = 6).
Using high performance liquid chromatography (HPLC) the concentrations ofmelphalan in the arterial and
venous perfusate (during ILP) and in the systemic circulation (during and after ILP) were measured. Areas
under the concentration time curves for perfusate (AUCa, AUCV) and systemic (AUCS) data were calculated.
In all three groups the peak concentrations of melphalan were much higher in the perfusate than in the
systemic circulation. The pharmacokinetic advantages of ILP can be quantified by the ratio of AUCa/AUCS,
median value 37.8 (2.1-131).
AUCG and AUC, were both significantly greater in Group B than in Group A (P values <0.01,
Mann-Whitney). In Groups B and C acceptable 'toxic' reactions occurred but were not simply related to
melphalan levels.
Our phase I study has allowed us to increase the dose of melphalan to 1.75 mg kg-', but we found no
pharmacokinetic advantage from divided dose administration.
The rationale for isolated limb perfusion (ILP) in the
management of cancer depends on the generation of high
levels of effective anticancer agent confined to the tumour-
bearing limb, thereby avoiding unacceptable systemic tox-
icity.
It is clearly important to establish whether the complex
and expensive technique of ILP genuinely achieves its major
aim i.e. maximum levels of melphalan in the tumour-bearing
limb and minimum systemic exposure.
ILP is effective in the management of locally advanced
malignant melanoma, and may be an effective adjuvant to
surgery for thick, high risk primary lesions. Having reviewed
our early experience of patients treated by ILP, it was
confirmed that, because of the absence of melphalan-induced
toxicity, there was scope for a phase I (dose escalating)
clinical study.
The study of pharmacokinetics is concerned with the
absorption, distribution, biotransformation and excretion of
drugs (Goodman et al., 1985). For a given dose these factors
govern the concentration of drug at the site of action and
they determine how the concentration varies with time.
We have studied melphalan pharmacokinetics in the con-
text of a phase I study of ILP.
The aims of our studies were:
(1) to measure melphalan concentrations in perfusate dur-
ing ILP, and compare these with the levels in the
systemic circulation during and after perfusion,
(2) to study the pharmacokinetics of melphalan in ILP, as
the dose was increased in a phase I study,
(3) to compare the pharmacokinetics of bolus dose with
divided dose administration.
Patients, materials and methods
Patient groups
Only patients having external iliac perfusion for malignant
melanoma were included in the study. The starting dose of
melphalan was 1.5 mg kg' body weight, which is the max-
imum dose recommended in the protocols on which our
technique is based (Krementz et al., 1987; Schraffordt Koops
et al., 1981). We planned that the dose would be escalated by
increments of 0.25 mg kg-' body weight.
Pharmacokinetic data was acquired on a total of 26 con-
secutive patients. The three main groups were:
A. Eleven patients who had isolated limb perfusion with a
melphalan dose of 1.5 mg kg-' body weight, given by
a single bolus injected into the venous line,
B. Nine patients who had isolated limb perfusion with a
melphalan dose of 1.75 mg kg-' body weight, given by
a single bolus (as Group A), and
C. Six patients who had standard isolated limb perfusion
except for the melphalan dose of 1.75mgkg-' body
weight, which was injected into the venous line in three
aliquots, at 0, 15 and 30 min during perfusion.
Group B comprises patients in the second stage of our
phase I study.
Groups C patients were treated with the same dose as
Group B, but it was given in divided amounts for com-
parison of the pharmacokinetic profile with that of Group B.
This was done because divided dose administration was
advised in the protocol of a Medical Research Council trial
of adjuvant isolated limb perfusion.
Local Ethical Committee approval was granted for all
studies described here.
Clinical ILP
With induction of general anaesthesia 1.5 grams of cefur-
oxime is given intravenously. A radial arterial line is inserted
for per-operative monitoring and for repeated systemic blood
sampling. Thermistor skin probes (Yellow Springs) are app-
lied to the skin of the affected limb, and the temperatures are
continuously displayed per-operatively on a monitor screen
(Siemens Sirecust). A stockingette (Tubigrip) on the leg, and
gamgee round the foot protect the skin from direct contact
with a heated water blanket (Hawksley Ripple-Heat system
with custom blanket) which is then wrapped around the limb,
and enclosed in sterile drapes.
Under routine balanced general anaesthesia the external
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iliac vessels are exposed retro-peritoneally via an oblique
incision in the iliac fossa. All minor branches of the external
iliac artery and all tributaries of the external iliac vein, from
the iliac bifurcation to the inquinal ligament, are ligated and
divided. The external iliac lymph nodes are inevitably excised
during this dissection to allow full vessel mobilisation. We do
not routinely clamp the internal iliac vein, but the obturator
vein is formally dissected and clamped.
Heparin (150 iu kg-') is given intravenously, prior to con-
trol of the vessels for cannulation. Polyvinyl chloride (P.V.C.)
cannulae (Bard and Cimid) are placed through a longitudinal
venotomy and arteriotomy and the cannulae are advanced so
that the tips lie in the femoral triangle inferior to the inguinal
ligament, and distal to where the lower edge of the tourni-
quet will lie. Each cannula is secured in place by two cotton
snares. A Steinmann pin is driven into the iliac crest and is
used to anchor a red rubber Esmarch bandage which tightly
encircles the root of the limb proximal to the tips of the
cannula, allowing perfusion of the femoral triangle.
The perfusion apparatus consists of a simple roller pump
(American Optical) in series with a disposable hybrid
oxygenator (Bard) which has an integral heat exchanger. The
pump/oxygenator (primed with 500 ml Ringer's lactate solu-
tion and 700 ml matched packed red cells plus 3000 i.u.
heparin, pre-warmed by the integral heat exchanger) circuit is
then opened to the arterial and venous cannulae, and the
limb is effectively 'on by-pass', supplied solely by the isolated
circuit. Unlike most other centres we oxygenate the perfusate
with 100% oxygen rather than 95% oxygen/5% carbon di-
oxide.
Figure 1 shows the isolated limb perfusion circuit in dia-
grammatic form.
When the isolated circuit is stable (after 3-5 min) 5 ml of
20% fluorescein is injected into the perfusate and, using a
portable ultra-violet lamp, the absence of a significant 'leak'
from the leg to the systemic circulation is confirmed by close
inspection of the skin above and below the tourniquet.
When the calf skin temperature is at least 37.5°C mel-
phalan is administered as a bolus of 1.5-1.75mg kg-' of
body weight (iliac perfusion).
Figure 1 Diagram of ILP circuit.
Perfusion continues for one hour, during which time flow
rate, dorsalis pedis arterial pressure, limb temperature and
transcutaneous oxygen (PtcO2) are monitored continuously.
After perfusion the limb circuit is 'washed out' with two
litres of Ringer's lactate, the tourniquet is removed, the
cannulae are withdrawn and the vessels are repaired. Appro-
priate doses of protamine sulphate are given to reverse the
heparin-induced anticoagulation.
The operation is completed about 150 to 180min after
induction of anaesthesia.
'Mock' ILP
'Mock' perfusions were performed on two occasions to study
how the levels of melphalan changed with time in a closed
circuit consisting of identical perfusion apparatus (i.e. ex-
cluding the patient from the circuit). In 'mock' ILP, mel-
phalan (100 mg) was added to the standard prime (one unit
of packed red blood cells+ 750ml Hartmann's solution).
The perfusate was allowed to recirculate at 37°C and 39°C
and samples were drawn, as in the clinical perfusions, at
5 min intervals for melphalan assay.
Perfusate sampling protocols
Paired 5ml samples of perfusate were obtained from the
arterial and venous ports of the oxygenator at 2, 5. 10, 15,
20, 25, 30, 35, 40, 45, 50 and 60 min. In clinical perfusions
5 ml samples were also drawn from the patient's radial
arterial line before perfusion, at 15, 30 and 60 min (during
perfusion), and at 75, 90, 120, 150, 180, 240 and 300 min
(after perfusion).
All perfusate and blood samples were collected in lithium
heparin tubes, mixed, and immediately placed on ice. Sam-
ples were centrifuged (2,500r.p.m. for 10min) within one
hour, then the plasma was separated and stored at - 20°C
for the minimum possible time before melphalan analysis by
HPLC.
Melphalan assay by HPLC
The sensitive and specific HPLC assay which we used is
based on an established method (Chang et al., 1978b).
10gIg of dansyl proline (Sigma) is added to a one millilitre
or less portion of the thawed plasma sample. In the analysis
dansyl proline acts as an internal standard, a substance
which is chemically similar to melphalan (the losses of which
parallel the losses of melphalan) but which generates a dis-
tinct peak on the chromatogram.
Four volumes of acetonitrile (BDH, HPLC Grade) with
1% hydrochloric acid (BDH, Analar Grade) are then added
to the plasma in 15 ml conical centrifuge tubes. The sample is
vortex-mixed immediately for 15 s and then centrifuged at
2,000 r.p.m. for 10 min to precipitate protein. The clear
supernatant is then transferred to 30 ml vials, and the volume
is reduced to 300gil or less under vacuum using a Buchler
vortex evaporator (approximately 25 min at 30°C). The
volume of the sample is then made up to 500pl, with 20%
methanol (BDH, HPLC Grade). The samples are transferred
to autosampler vials, sealed and loaded in the autosampler.
Une The samples are injected by an Altex autosampler (Model
500, Beckman RIIC) which has a 100gIL loop (50 p.s.i.). An
Altex solvent programmer (Model 420, Beckman RIIC) and
an Altex solvent pump (Model IOOA, Beckman RIIC) deliver
the mobile phase at 1.5 ml/min to a 250 x 4 mm stainless
steel column (Waters), packed with giBondapak C18
(Waters). The elution buffer consists of 50 ml 0.01 M
NaH2PO4 and 50 ml methanol titrated to pH 3.0 with phos-
phoric acid (BDH, Analar Grade).
Eluted melphalan and dansyl proline were detected by a
UV detector (Model LC-UV, Pye Unicam) set at 261 nm
wavelength. The UV spectrophotometer range was 0.01 or
0.02 A.U. The recorder was set at 1 mv and the chart run at
10 cm h'.
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DP88, Pye Unicam) which measures the areas under peaks
on the elution chromatogram. The tR (retention time) value
for melphalan was 6.68 min, and for dansyl 9.57 min.
The extraction of melphalan from plasma and perfusate
was 89%. Standard curves were generated which confirmed
the accuracy of the method over the range of melphalan
concentrations in plasma 0.2-200 gg ml1' (correlation co-
efficient, r = 0.9894). The coefficient of variation (standard
deviation/mean x 100) for 20 identical samples at 2Ig ml-'
in plasma was 4.2%.
Pharmacokinetic analysis
The concentration time curves for bolus administration could
be described by bi-exponential curves, fitted by the method of
non-linear least squares using an 'in-house' programme based
on the Marquardt algorithm (Marquardt, 1963).
Incomplete mixing in the immediate phase after injecting
the bolus of melphalan resulted in relatively wide variation in
the levels measured in perfusate at the 2 min time point.
These values were therefore omitted from graphical illustra-
tion and calculations.
To estimate the tissue exposure to (or bio-availability of)
melphalan during isolated limb perfusion, the area under
each concentration time curve was calculated for clinical and
mock perfusions. The area under the curve (AUC) was cal-
culated by the trapezoidal rule, from time zero to sixty
minutes (AUCo 60) for the arterial and venous concentrations
in perfusate (AUCa and AUCV). The same method was used
to calculate the total AUC (AUCO-.) for systemic exposure
to melphalan during and after perfusion (AUCS).
Tissue uptake of melphalan was estimated using a method
based on the Fick principle (Ganong, 1981). The amount of
a substance taken up by an organ per unit of time is equal to
the arterial level minus the venous level (A-V difference),
multiplied by blood flow.
i.e. (1) E= (A-V) x Q
when E = extraction rate, A = arterial level, V = venous
level and Q = flow rate; assuming that arterial blood is the
sole source of the substance.
Considering a controlled system like the isolated limb per-
fusion circuit, the amount of substance extracted by the limb
can be estimated as being equal to the extraction rate multip-
lied by duration ofperfusion. When a series of paired arterial
and venous measurements are available, the AUCa and
AUCV can be introduced into the equation.
i.e. for melphalan in isolated limb perfusion,
(2) MELe, = E x t = (AUCa - AUCV) x Q
when MEL,X = amount of melphalan extracted,
E = extraction rate, t = duration of perfusion,
AUCa = arterial AUC, AUCV = venous AUC,
and Q = flow rate.
Assuming that Q is constant, and that MELCX is accounted
for by tissue uptake alone.
Results
Perfusate versus systemic melphalan levels
Illustrating the data for Group A, Figure 2 shows that the
perfusate levels of melphalan are much higher than systemic
levels during and after isolated limb perfusion.
Table I shows the arterial and venous AUCO-60, and the
systemic AUCo0, for each patient in Groups A, B and C. It
is clear that within all three groups the median AUC, is
much lower than the AUCa or AUCV. No statistically
significant difference was detected between the AUCS values
of Group A versus Group B, or of Group B versus Group C
(Mann-Whitney).
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Figure 2 Mean concentrations of melphalan in perfusate during
the hour of ILP -A -; and in the systemic circulation during
and after ILP -0-. (Error bars omitted where s.e.m. <sym-
bol size).
Pharmacokinetics and Phase Istudy
Figure 3 shows the curves describing arterial and venous
melphalan levels during isolated limb perfusion in Groups A
and B. The mean arterial and venous melphalan concentra-
tion time curves for Group A and Group B can be fitted to
lines described by bi-exponential equations of the form:
Ct = A.e-' + B.e-P'
where Ct is concentration at time 't' minutes,
A and B are intercepts on the log concentration
axis at t = 0 min, of the two linear components of
the curve describing logC against time,
and a and P are the rate constants of these two
components (Bowman & Rand, 1980).
The values for the parameters A, B, a and P, are given in
Table II, along with the half-life (t1) values derived from each
individual concentration time curve.
Lines were also fitted to describe melphalan concentrations
in perfusate during 'mock' perfusion at 37°C and 39°C
(Figure 4) according to the mono-exponential equations:
C, = 98.4 x e-0013.' for the 37°C experiment,
where ti = 51.6 min;
and Ct= 104 x e-002 for the 39°C experiment,
where t1 = 36.6 min.
It can be seen that the half-life of melphalan in the P phase
tip of clinical perfusions is longer than the tx and it approx-
imates to the values for the half-life times in the 'mock'
perfusions. Table I and Figure 3 show that increasing the
dose of melphalan from 1.5 to 1.75 mg kg' body weight
resulted in higher levels of melphalan in perfusate. Compar-
ing drug exposure in perfusate (Table I) the values for AUCa
and AUCV are both significantly greater in Group B than in
Group A (P values <0.01, Mann-Whitney). The ratio
AUVa/AUCs for groups B and C combined was significantly
greater than for Group A (P<0.05, Mann-Whitney).
The regional toxicity for patients in the phase I study is
summarised in Table III according to a simple clinical
grading system-from grade I, no subjective or objective
evidence of reaction to grade V, a reaction which may
require amputation (Wieberdink et al., 1982). In group B we
saw Wieberdink grade III reactions on two occasions (con-
siderable erythema and/or oedema with some blistering and
slightly disturbed mobility). Since we had not seen such
toxicity in either group A or in a previous pilot study of 26
patients it was decided that 1.75 mgkg-' body weight should
be the maximal dose for our system.
Bolus or divided dose?
Figure 5 shows the curves describing melphalan concentra-
tion after bolus (Group B) or divided dose (Group C)
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Table I Melphalan pharmacokinetics in isolated limb perfusion: Dose of melphalan,
perfusateAUCaand AUCV datafor individual patients in Groups A, B and Ccompared with
the AUCO of systemic concentrations of melphalan (AUCS)
Dose
(mg) AUC, AUC, AUC, AUCO/AUCs
Group A 100 597 504 26.5 22.5
(1.5mg kg-' bolus) 75 780 932 48.9 15.95
100 919 848 37.5 24.5
125 1140 957 30 38
150 806 748 246 3.28
70 1011 579 287 3.52
75 858 869 402 2.13
100 1324 1360 92.3 14.34
125 1229 1187 98.2 12.5
130 1158 1087 9.5 121.9
100 1508 1105 29.4 51.3
Median 100 1011 932 48.9 15.95
Group B 90 1204 984 361 3.33
(1.75 mg kg-' bolus) 165 1912a 1680 231 8.27
140 1649a 2083 26.4 62.5
70 1144 900 9.5 120.42
135 4011 3056 74.3 54
140 2720 2030 70.1 38.8
105 1758 1570 34.6 50.8
90 1019 963 27.2 37.5
120 1275 1425 24.9 51.2
Median 120 1649 1570 34.6 50.8
Group C 175 2116b 1903 62.8 33.7
(1.75 mg kg-' divided dose) 84 1443a 1326 56.4 25.5
100 1129 1018 8.6 131
100 988 902 9.7 101.8
120 2128 2024 25.2 84.4
89 2180 1950 35.7 61
Median 100 1779 1614 30.5 72.7
The unit for AUC is thejig min ml-'. Toxicity: aGrade III; bGrade IV (Wieberdink et al.,
1982).
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Table II a Summary of the values obtained for the best-fit lines
describing concentration time curves for melphalan in arterial and
venous perfusate in Groups A and B
Paraneter
A a B
Group A
Arterial 48.9 0.1 16.8 0.01
Venous 42.8 0.09 13.7 0.01
Group B
Arterial 86.5 0.09 21.4 0.003
Venous 66.5 0.19 44.3 0.02
0 5 10 15 20 25 30 35 40 45 50 55 60
Time (minutes)
Figure 3 Mean concentrations of melphalan in the perfusate of
Group A: - -A - - A arterial; - -0 - - A venous; and Group B:
A - B arterial; -* B venous.
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TableH bValuesforhalf-lifeofalphaand betaphasesofthefittedlines
(tja and tP) for arterial and venous perfusate in Groups A and B
tl( ti
(min) s.e.m. (min) s.e.m.
Group A
Arterial 12.27 1.06 54.45 8.64
Venous 13 0.813 33.4 3.25
Group B
Arterial 13.8 0.76 57.17 11.47
Venous 17.33 2.64 44 4.91
administration of melphalan 1.75 mg kg-' body weight.
From data in Table I, there is no significant difference
between Group B and Group C (Mann-Whitney) in either
the AUCa, AUCV or AUCS. Table III shows that the regional
toxicity was also similar in Groups B and C.
Calculations oftissue uptake ofmelphalan
The results for the calculation of MELex, according to the
Fick principle, in the three groups of patients are given in
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Figure 4 Lines of best-fit describing concentrations ofmelphalan
during 'mock' ILP at 37°C -A-; and at 39°C . O .
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Table III Regional toxicity in patients treated by isolated limb
perfusion in pharmacokinetics studies
No. patients
Wieberdink Group B Group C
toxicity Group A (1.75 mgkg-' (1.75 mg kg-'
gradea (1.5 mg kg-') bolus) divided dose)
I 1 0 0
II 10 7 4
III 0 2 1
IV 0 0 1
V 0 0 0
'Wieberdink et al., 1982.
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Figure 5 Mean concentrations of melphalan after a dose of
1.75 mg kg-' given as a bolus to Groups B A B arterial;
* B venous; and in divided dose to Group C - C
arterial; -0--- C venous.
Table IV, along with the same calculation for a 'mock'
perfusion at 39°C. The ti of melphalan in human plasma in
vitro was 114 min at 37°C and 60 min at 42°C. In the 'mock'
perfusions the t1 values were less than in vitro incubations,
suggesting that hydrolysis proceeds more rapidly or that a
significant amount of melphalan may be 'lost' to the con-
stituents of the circuit and to the cellular components of the
perfusate. Assuming that hydrolysis is similar in the three
clinical groups, the combined results of the calculations in
Table IV suggest that approximately 25-40% of admini-
stered melphalan distributes to the tissues of the leg (after
correction for the proportion 'lost' to the circuit) during
isolated limb perfusion.
The slopes of the concentration time curves after bolus
dose administration (Figures 3 and 5, Table II) indicate that
melphalan disappears from perfusate more rapidly in the first
half-hour of perfusion.
Table IV Melphalan pharmacokinetics in isolated limb perfusion:
Calculated uptake of melphalan by tissues of the leg according to
Formula (2): MELex = (AUCa-AUCv) x Q
Group A (n = 11)
MEL,, = (1030-925) x 443 = 46.5 mg = 44% of mean dosea
Group B (n = 9)
MELex = (1855- 1633 x 316=70 mg = 60% of mean dose"
Group C (n = 6)
MELe, = (1664- 1520) x 331 =47.6 mg = 43% of mean dosea
In the clinical groups, mean values for AUC and flow are used. aEach
ofthese values appears to be an overestimate, unless one proposes that
thereisveryaviduptakeofmelphalan bythe tissues oftheleg. Hence the
same calculation is applied to the 39'C mock perfusion data:
MELex = (3761-3705) x 400 = 22 mg = 22% of dose, which is the
proportion 'lost' to the cellular components of perfusate and to the
perfusion circuit.
Discussion
Regional and systemic exposure to melphalan
There have been a few studies of drug levels achieved in
perfusate during ILP with melphalan (Benckhuijsen et al.,
1986; Hafstrom et al., 1984; Tonak, 1981; Briele et al., 1985;
Minor et al., 1985) but there is little data on systemic levels
ofmelphalan during ILP (Hafstrom et al., 1984; Minor et al.,
1985), and the total systemic exposure to melphalan has not
been quantified. In our study the peak concentrations of
melphalan were much higher in perfusate than in the
systemic circulation in all three groups (ratios of peak per-
fusate: systemic levels in tsg ml-' - A 45:0.76, B75.3:0.53, C
44:0.4).
Studies describing the pharmacokinetics of high-dose
systemic intravenous melphalan (assay by HPLC) have
shown mean AUC values of approximately 400 g minml-'
in adults (Stotter et al., 1987; Ardiet et al., 1986; Gouyette et
al., 1986). From Table I it can be seen that in all our patients
the AUCa and AUCV are both much higher than this.
We have measured systemic melphalan levels during and
for several hours after perfusion to determine the total
systemic exposure (Table I), described by the systemic
AUCO <:o (AUCs). In the great majority the AUCS is much
lower, being over 300lg min ml' in only two patients. The
ratio of AUCa/AUCs gives a value which describes the
pharmacokinetic advantage achieved by ILP. Although there
was a wide range of AUCa/AUCS, the greater values achieved
with the larger dose suggest that we should use 1.75 mg kg-'
rather than 1.5 mg kg-'.
Systemic exposure to melphalan-leak and washout
Good surgical technique, including awareness of anatomical
variations and thorough dissection of the vessels, helps to
prevent sudden major 'leaks' to the systemic circulation dur-
ing perfusion. Even with perfect operative technique, how-
ever, there is a variable but inevitable escape from the
'isolated' limb and this may be due to 'leakage' through
intra-osseous femoral vessels, vessels passing through the
obturator foramen or calcified branches of the cruciate
anastomosis which may not be occluded by the tourniquet.
After ILP a proportion of the melphalan taken up by the
tissues of the limb may diffuse back into bloodstream and be
'washed out' into the systemic circulation.
Studies have shown, using radio-labelled albumin, that the
measured 'leak' from perfusate to the systemic circulation
during ILP may be as much as 40% (Lejeune & Ghanem,
1987; Hafstrom et al., 1984; Briele et al., 1985), despite very
low systemic melphalan levels during perfusion (Hafstrom et
al., 1984; Lejeune & Ghanem, 1987). On such evidence it is
claimed that the radio-labelled albumin method simply over-
estimates the 'leak' of melphalan (Lejeune & Ghanem, 1987)
but this line of argument neglects several important factors.
Albumin is a relatively stable large molecule which will tend
to remain within the vascular compartment. In contrast mel-
phalan is continually degraded by hydrolysis in aqueous
environments, and the fraction of melphalan which 'leaks'
from the isolated limb to the systemic circulation will parti-
tion within a much larger volume of distribution (intravas-
cular and interstitial fluid). Furthermore some of the mel-
phalan taken up by the tissues (of the perfused leg and the
rest of the body) may be protected from hydrolysis by
associating with tissue proteins (Chang et al., 1978a; Ehrsson
& Lonroth, 1982) and released later, when the melphalan
concentration gradients are reversed after perfusion. Thus a
significant fraction of the administered melphalan dose could
'leak' and be 'washed out' from the perfusate to systemic
circulation, yet produce only low systemic plasma concentra-
tions.
Pharmacokinetics ofbolus administration
The concentration time curves describing melphalan in per-
fusate after bolus administration (Figure 3) are biphasic,
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conforming to a two compartment model. In groups A and B
the ti (half-life) for the first, or a phase, was shorter than in
the 1B phase. The concentration time curves for 'mock' per-
fusions were monophasic (Figure 4), conforming to a one
compartment model. The ti in the ,B phase of clinical per-
fusion is similar to the half-life observed throughout 'mock'
perfusions, when the rate of decay depends on hydrolysis
plus losses in the perfusion circuit. It is inferred that the
rapid loss of melphalan from perfusate in the a-phase of
clinical ILP is mainly due to uptake by the tissues of the
limb.
Phase Istudy and dosimetry
To take full advantage of the potential benefit of ILP it is
important that the tumour-bearing limb is subjected to the
maximal safe melphalan exposure, which is a function of
time and concentration and which can be quantified by the
perfusate AUC. The dose of melphalan used in isolated limb
varies from centre to centre. In most series the dose is
calculated on the basis of body weight, and the most com-
monly recommended dose for an iliac perfusion is 1-1.5 mg
per kilogram of body weight (Krementz, 1986; Shingleton et
al., 1975; Bulman & Jamieson, 1980; Storm & Morton, 1985;
Ghussen et al., 1984; Schraffordt Koops et al., 1981). In a
few studies it has been suggested that doses as high as 2 mg
per kilogram of body weight can be given (Rosin & West-
bury, 1980; Fontaine & Jamieson, 1974).
There is a trend towards melphalan dosimetry for ILP
according to limb volume (Krementz, 1986). However the
measurement of limb volume by water displacement (Wieber-
dink et al., 1982) can be a cumbersome procedure, particular-
ly in older patients. There have been no reports describing
the accuracy and reproducibility of limb volumetry by water
displacement. In a small prospective study, it was found (Van
Os et al., 1985) when using 10 mg 1' of limb volume that the
equivalent of 1.77 mg kg-' body weight could be given safely
in their patients (their previous mean dose 1.44 mg kg-').
Similar results would have been obtained in their study if the
higher doses had simply been administered on the basis of
body weight.
For patients of 'average build' body weight is an accep-
table basis on which to calculate dose in ILP, but the use of
limb volume dosimetry may be of specific value in the
management of patients who have an abnormal habitus, or
amputees.
It is generally accepted that a lower total dose of mel-
phalan should be used when perfusing smaller regions of the
body e.g. axillary perfusion. In this setting the limb volume
method for dosimetry results in doses which are probably
inadequate (Van Os et al., 1985) since they are even lower
than those calculated on the basis of body weight (Krementz
et al., 1985). Although the rationale is plausible the practical
benefits of routine dosimetry by limb volume are unclear.
It has been recommended that other factors to be con-
sidered when calculating the dose of melphalan to be
administered include complexion and hair colour (McBride &
Clark, 1971; Schraffordt Koops et al., 1977)-fair-skinned
red-heads being supposedly more susceptible to toxicity than
those of a dark complexion but these recommendations have
not been validated.
Body weight is obtained easily and reproducibly on the
ward, without special equipment. We believed that since no
formal phase I study had been carried out using body weight
for dosimetry such a study should be done.
In the phase I study it was found that the dose of mel-
phalan could be increased form 1.5 mg kg-' body weight
(Group A) to 1.75 mg kg-' (Group B) with an acceptable
slight increase in regional toxicity (Table III). The peak levels
of melphalan were higher after 1.75 mg kg-' than after
1.5 mg kg', and the higher levels were maintained during
perfusion. Comparison of the perfusate AUC data for
Groups A and B (Table I) confirms that the higher dose
resulted in significantly greater bio-availability of melphalan
within the limb, without any increased systemic exposure. In
no patient was a significant leak suspected but there was a
wide range in AUCS (8.6-402 tg min ml-'). None of the five
cases which had an AUCS value greater than 200 ytg min ml-'
suffered significant systemic toxicity and, in particular, there
was no detected bone marrow toxicity. This may be due to
the relatively slow release of melphalan from the tissues of
the perfused limb, which will be less likely to produce high
peak systemic levels and 'saturate' the bone marrow than a
single large intravenous bolus as given during high dose
systemic melphalan therapy.
In reports of ILP it is remarkable that the volume of
perfusate, which critically determines the effective concentra-
tion of melphalan, has been so neglected. In fact, the volume
of prime is often omitted in reports (Storm & Morton, 1985;
Schraffordt Keeps et al., 1987; Sugarbaker & McBride, 1976;
Mikhail et al., 1984; Rege et al., 1983), even in studies of
melphalan pharmacokinetics (Hafstrom et al., 1984; Oster-
held et al., 1988).
Formerly it was believed that the perfusate volume was
mainly determined by the prime (Wieberdink et al., 1982),
but the total volume of perfusate also hncludes blood trapped
in the limb vessels at the start of perfusion. The volume of
prime is easily measured directly but the volume of blood
trapped in the limb vasculature is probably more variable.
The volume of priming fluid varies in descriptions of ILP
according to different authors from 600 ml (Krementz et al.,
1987; Hansson et al., 1977) to two litres (Rosin & Westbury,
1980). We used a fixed volume of prime and a standard
cannulation sequence, but some of the variability in our
pharmacokinetic results is likely to be due to the variable
volume of trapped limb blood which contributes to the total
perfusate volume.
Elegant methods have recently been described for
estimating perfusate volume (Benckhuijsen et al., 1986;
Lejeune & Ghanem, 1987). The validity of these methods has
not been confirmed, but the attraction is that, based on
pharmacokinetic parameters, accurate knowledge of the per-
fusate volume would allow the administration of a dose
calculated to produce a predictable concentration (Siddik et
al., 1989) in perfusate. Assuming that cytotoxic effect and
toxicity are mainly dependent on melphalan concentration
and AUC, this would represent an advance on dosimetry by
body weight or limb volume. In an ideal situation, this new
approach would be combined with knowledge of the relative
sensitivities of an individual patient's tumour (and normal
tissue) to cytotoxic drugs, allowing 'tailored' therapy.
Bolus ofdivided dose?
The original rationale for dividing the dose was to minimise
the consequences of 'leakage' and it is not clear whether
there is any pharmacokinetic advantage in bolus or divided
dose administration.
Once we determined that melphalan could be safely given
as a bolus dose of 1.75 mg kg-' body weight (Group B,
Table III), we set out to discover whether divided dose
administration at this dose level (Group C) resulted in
greater AUCa and AUCV values. There was no significant
difference in these values between the two groups. However
one patient in Group C (total dose 175 mg; AUCa
2116 min Lg ml') suffered a severe reaction (Wieberdink
Grade IV).
We have shown that up to 165 mg of melphalan can be
given safely as a bolus (calculated as 1.75 mg kg-' body
weight) during ILP, and that there is no apparent pharma-
cokinetic advantage in divided dose administration.
Calculations oftissue uptake ofmelphalan
It would clearly be desirable to know what proportion of
administered melphalan is taken up by the tissues of the leg,
and also to discover how that proportion is distributed
among the different tissues (especially any differences
between benign and malignant). With this knowledge the
effects of various manipulations (e.g. changing dose of drug,ADVANTAGES OF ISOLATED LIMB PERFUSION 165
duration of perfusion or temperature) could be assessed.
Attempts have been made to estimate the proportion of
administered melphalan which distributes to the tissues of the
leg semi-quantitatively (Briele et al., 1985) and quantitatively
(Benckhuijsen et al., 1988). One previous publication des-
cribes the measurement of tissue concentrations of melphalan
achieved by ILP (Stotter et al., 1987) in three patients. It has
been suggested that cellular uptake mechanisms for mel-
phalan may be saturable in the perfused limb (Benckhuijsen
et al., 1986; Briele et al., 1985).
This is the first study where paired arterial and venous
samples of perfusate were obtained for melphalan analysis
throughout the hour of ILP. Hence we could use the per-
fusate AUC data in Formula (2) which is derived from the
Fick principle. Uncorrected, the results tend to overestimate
the amount of melphalan taken up by the leg (MELex) and
45-60% of administered dose. It is important to realise that
the melphalan concentration measured is the plasma con-
centration, and that although hydrolysis is corrected for,
melphalan is known to rapidly associate with the cellular
components of blood (Briele et al., 1985; Greig et al., 1987 in
a ratio of cells:plasma equal to approximately 1:1 (Benck-
huijsen et al., 1986). During the hour of perfusion a fraction
of the administered dose (approximating to the haematocrit
as %) partitions to the red blood cells, and this accounts for
the 22% correction factor as calculated by applying Formula
(2) to the 'mock' perfusion (see Table IV).
Dividing the dose (Group C) may allow continued drug
uptake throughout the period of perfusion but it is not clear
whether this is advantageous, or whether it may be preferable
to generate early high peaks by bolus administration. Yet
another strategy would be to administer the cytotoxic by
infusion into the arterial line of the circuit, while slowing the
flow rate to maximise the effect of first-pass extraction.
Homogeneous mixing of melphalan within the perfusate
might be achieved by injecting the drug via the arterial line
during the course of one circulation time (Wieberdink et al.,
1982).
Estimates of tissue uptake based on changes in perfusate
concentration of melphalan (Briele et al., 1985; Benckhuijsen
et al., 1988), including our Fick based calculations, are
merely indicators of the dynamic situation in the limb as a
whole, but the critical question relates to the concentration of
melphalan which is achieved at the site of action i.e. tumour
cell DNA. The changes in perfusate concentration of mel-
phalan will be, at best, crude indicators of critical events
which govern the passage of melphalan from the capillary
lumen to the melanoma cell nucleus. The duration of ILP
with melphalan is usually one hour (Krementz et al., 1987;
Martijn et al., 1986; Benckhuijsen et al., 1986) but it may be
as short as 45 min (Mikhail et al., 1984) or as long as two
and a half hours (Stehlin, 1969; Hafstrom et al., 1984).
There is no clinical trial based evidence to suggest that the
optimal duration for ILP has been found. In spite of the
short half-life of melphalan in aqueous solution, and the
relatively short time of exposure involved in ILP, it may be
that the drug is somewhat protected from hydrolysis once it
leaves the vascular compartment. Furthermore, the drug in
the tissues may continue to form cross-links for hours after
exposure (Hansson et al., 1987). Hence there may be
relatively little therapeutic gain achievable by prolonged
clinical ILP, if maximal safe doses are already being given.
We believe that it would be premature to advocate shorter
periods of perfusion.
Conclusions
Isolated limb perfusion successfully and consistently achieves
the aim of exposing the tumour-bearing limb to high concen-
trations of melphalan, while minimising systemic exposure.
Following bolus administration of melphalan the concent-
ration time curve is biphasic, with a mean ttx of
12.27-17.33 min, and mean tip of 33.4-57.17 min. Mel-
phalan seems to be taken up by the tissues of the leg mainly
during the first 30 min of isolated limb perfusion. However
perfusion should last longer than 30 min to maintain the
concentration gradients which drive the drug through
diffusion barriers to the target cells.
In a phase I study we have shown that, using our standard
technique of isolated limb perfusion, melphalan can be given
safely in a bolus dose of 1.75 mg kg' body weight (up to
165 mg total dose). This higher dose yielded a significantly
greater value of AUCa/AUCs than did 1.5 mg kg-.
There was no pharmacokinetic advantage in divided dose
administration, and no increased regional toxicity as a conse-
quence of the high peak levels which occur during bolus dose
administration.
R.N.S. was supported by a grant from the Cancer Research
Campaign (SPI837).
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